Literatura académica sobre el tema "Neuroendocrine transdifferentiation"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Neuroendocrine transdifferentiation".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Neuroendocrine transdifferentiation"
Sergeant, Camille, Christel Jublanc, Delphine Leclercq, Anne-Laure Boch, Franck Bielle, Gerald Raverot, Adrian F. Daly, Jacqueline Trouillas y Chiara Villa. "Transdifferentiation of Neuroendocrine Cells". American Journal of Surgical Pathology 41, n.º 6 (junio de 2017): 849–53. http://dx.doi.org/10.1097/pas.0000000000000803.
Texto completoStone, Louise. "A novel mechanism of neuroendocrine transdifferentiation". Nature Reviews Urology 15, n.º 5 (20 de marzo de 2018): 263. http://dx.doi.org/10.1038/nrurol.2018.40.
Texto completoCordeiro-Rudnisky, Fernanda, Yue Sun y Rayan Saade. "Prostate Carcinoma With Overlapping Features of Small Cell and Acinar Adenocarcinoma: A Case Report". American Journal of Clinical Pathology 152, Supplement_1 (11 de septiembre de 2019): S66—S67. http://dx.doi.org/10.1093/ajcp/aqz113.072.
Texto completoQuintanal-Villalonga, Alvaro, Hirokazu Taniguchi, Yingqian A. Zhan, Jacklynn V. Egger, Umesh Bhanot, Juan Qiu, Elisa de Stanchina et al. "AKT inhibition as a therapeutic strategy to constrain histological transdifferentiation in EGFR-mutant lung adenocarcinoma." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e21166-e21166. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21166.
Texto completoYuan, Ta-Chun, Suresh Veeramani y Ming-Fong Lin. "Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells". Endocrine-Related Cancer 14, n.º 3 (septiembre de 2007): 531–47. http://dx.doi.org/10.1677/erc-07-0061.
Texto completoVon Amsberg, Gunhild, Sergey Dyshlovoy, Jessica Hauschild, Verena Sailer, Sven Perner, Anne Offermann, Lina Merkens et al. "Long-term taxane exposure and transdifferentiation of prostate cancer in vitro." Journal of Clinical Oncology 41, n.º 6_suppl (20 de febrero de 2023): 254. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.254.
Texto completoQuintanal-Villalonga, Alvaro, Hirokazu Taniguchi, Yingqian A. Zhan, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah et al. "Abstract 658: AKT pathway as a therapeutic target to constrain lineage plasticity leading to histological transdifferentiation". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 658. http://dx.doi.org/10.1158/1538-7445.am2022-658.
Texto completoFrigo, Daniel E. y Donald P. McDonnell. "Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation". Molecular Cancer Therapeutics 7, n.º 3 (marzo de 2008): 659–69. http://dx.doi.org/10.1158/1535-7163.mct-07-0480.
Texto completoPatel, Girijesh, Sayanika Dutta, Mosharaf Mahmud Syed, Sabarish Ramachandran, Monica Sharma, Venkatesh Rajamanickam, Vadivel Ganapathy et al. "TBX2 Drives Neuroendocrine Prostate Cancer through Exosome-Mediated Repression of miR-200c-3p". Cancers 13, n.º 19 (7 de octubre de 2021): 5020. http://dx.doi.org/10.3390/cancers13195020.
Texto completoTurner, Leo, Andrew Burbanks y Marianna Cerasuolo. "Mathematical insights into neuroendocrine transdifferentiation of human prostate cancer cells". Nonlinear Analysis: Modelling and Control 26, n.º 5 (1 de septiembre de 2021): 884–913. http://dx.doi.org/10.15388/namc.2021.26.24441.
Texto completoTesis sobre el tema "Neuroendocrine transdifferentiation"
Guo, Yingbo. "Rôle du cil primaire au cours de la transdifferentiation neuroendocrine du cancer de la prostate". Electronic Thesis or Diss., Université Côte d'Azur, 2024. http://www.theses.fr/2024COAZ6005.
Texto completoProstate cancer is one of the most common malignancy cancers worldwide. 95% of PCa patients are diagnosed with adenocarcinoma of the prostate showing no expression of neuroendocrine markers. De novo neuroendocrine prostate cancer is a rare and aggressive subtype of prostate cancer, characterized by neuroendocrine markers expression. Approximatively 20% of adenocarcinoma cases progress to neuroendocrine prostate cancer following androgen deprivation therapy. The potential side effect of androgen deprivation therapy, resulting in neuroendocrine differentiation of adenocarcinoma of the prostate, brings a novel challenge for prostate cancer treatment. While many molecular mechanisms of neuroendocrine differentiation have been described, the timing of the neuroendocrine differentiation occurrence and how these driving factors result in neuroendocrine differentiation remain unclear.The primary cilium is a non-motile organelle present in nearly all human cells. Loss of primary cilium has been observed in various cancers, including clear cell Renal Cell Carcinoma (ccRCC) and PCa. Previous findings from our research team identified a distinct subgroup of pataients within ccRCC, which retained primary cilium and exhibited resistance to therapy. The presence of primary cilium was characterized by the GLI1+/IFT20+ signature. Under hypoxic conditions, primary cilium was inhibited due to stabilization of HIF-1α, correlating with increased aggressiveness of ccRCC. Considering that both ccRCC and prostate cancer are typically described as cancer lacking PC, we postulated the existence of a unique subgroup in prostate cancer exhibiting primary cilium presence associated with higher aggressiveness.We developed multiple approaches to enhance in the number of primary cilium numbers in both normal prostate cells and prostate cancer-like cells in 2D or 3D cell culture settings. This increase was correlated with a reduction in proliferation and growth of 3D structures. Notably, these methods maintained their effectiveness in inducing primary cilium numbers even under hypoxic conditions. Our findings confirmed the robustness of the GLI1+/IFT20+ signature in increasing primary cilium numbers in normal cells, while this signature was less pronounced in prostate cancer-like cells. In parallel, we discovered that the restoration of primary cilium in prostate cancer cells is associated to the neuroendocrine transdifferentiation of prostate cancer. Furthermore, the regulation of primary cilium is linked to the cancer aggressiveness.Our research provides evidence that primary cilium is present in a more aggressive subgroup of prostate cancer patients, similar to what is observed in ccRCC. Analyzing the role of primary cilium in the transdifferentiation of prostate cancer provides new insights into potential treatment strategies
Actas de conferencias sobre el tema "Neuroendocrine transdifferentiation"
Li, Yinan. "Abstract 4473: SRRM4 drives treatment-induced neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition". En Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4473.
Texto completoBeshiri, Mike L., Caitlin M. Tice, Adam G. Sowalsky, Crystal Tran, Fatima Karzai, William Dahut y Kathy Kelly. "Abstract 5020: A patient-derived organoid model of neuroendocrine prostate cancer transdifferentiation informing the role of the BAF complex component ARID1A". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5020.
Texto completo